Plaintiffs properly allege falsity and materiality regarding some statements made about company’s breast cancer screening products. A securities fraud class action contended that a company made a series of public statements about its breast cancer screening products that were materially false or misleading. The Ninth Circuit held that plaintiffs properly alleged falsity and materiality as to some, but not all, of defendants’ statements. Among other things, the panel held that plaintiffs sufficiently pleaded that alleged statements describing one product as cleared by the FDA were false. The panel also determined that an opinion statement regarding FDA clearance risk was misleading by omission, and the omissions were material.(8/18/2017) In Re Atossa Genetics Inc. Securities Litigation.